• ABT-199 for Reliable BCL-2 Apoptosis Assays

  2026-09-30

  This scenario-driven guide explains how ABT-199 (GDC-0199), Bcl-2 inhibitor, potent and selective (SKU A8194), can improve experimental design for viability, proliferation, and apoptosis assays. It covers mechanism, DMSO handling, dose selection, data interpretation, and practical vendor-selection criteria for hematologic malignancy research.

• Amitriptyline HCl: Practical QC and Protocols

  2026-09-30

  Amitriptyline HCl (SKU B2231) provides a defined small-molecule reference for receptor inhibition, solution preparation, and quality control in neuropharmacology research. This guide supports controlled in vitro assay setup and exploratory mood disorder or neurodegenerative disease model work, but it should not be used to infer clinical efficacy or disease-modifying activity without independent validation.

• TMRE mitochondrial membrane potential assay kit guide

  2026-09-29

  Build a quantitative mitochondrial depolarization workflow for apoptosis, sodium-overload, tissue, and purified-mitochondria models. This guide pairs the TMRE mitochondrial Membrane Potential Assay Kit with CCCP controls, plate-based optimization, and mechanistic interpretation grounded in recent NECSO research.

• Bromodomain Inhibitor, (+)-JQ1: Assay Guide

  2026-09-29

  This scenario-based guide explains how Bromodomain Inhibitor, (+)-JQ1, SKU A1910, can improve interpretation and reproducibility in viability, proliferation, and apoptosis workflows. It connects BRD4 biology, solvent control, dose–time optimization, and product-handling decisions to published BET-inhibitor evidence.

• HDAC Inhibitors Repress NUT Function in NUT Carcinoma

  2026-09-28

  Shiota and colleagues developed a dCas9-based GFP reporter screen that identified chemically diverse HDAC inhibitors as suppressors of NUT-dependent transcription. The study connects HDAC inhibition with loss of BRD4-NUT megadomain activity, induction of differentiation, and improved tumor control in xenograft models, providing a mechanistic rationale for therapeutic investigation in NUT carcinoma.

• Thermogelling Hydrogel Improves Erythromycin for Keratitis

  2026-09-28

  Zheng and colleagues developed a thermosensitive BPOSS–BPEP hybrid hydrogel to address erythromycin’s poor aqueous solubility and short residence on the ocular surface. In a mouse model of Staphylococcus aureus keratitis, the drug-loaded formulation showed therapeutic activity and reported biocompatibility, supporting further study of hydrogel-based ocular delivery.

• VX-765 and the Logic of Inflammatory Cell Death

  2026-09-27

  Caspase-1 inhibition can help researchers separate inflammatory cytokine maturation from the broader consequences of cell death. This article connects VX-765 and its active metabolite VRT-043198 to a practical translational framework, while distinguishing caspase-1-dependent pyroptosis from the RNA Pol II-triggered apoptosis described in recent research.

• Rhodamine B for Nanomedicine Imaging Workflows

  2026-09-26

  Use Rhodamine B as a practical fluorescence readout for cell labeling and microscopy—not as a stand-in for therapeutic efficacy or proof of nanoparticle delivery. This workflow connects the trypsin-responsive pancreatitis nanomedicine study to careful tracer validation, with controls that distinguish cell-associated signal from free dye.

• RP3-340N1.2 Drives IL-6 Signaling in NSCLC

  2026-09-25

  A 2026 study links the long non-coding RNA RP3-340N1.2 to IL-6 mRNA stability in non-small cell lung cancer, identifying an interaction with the RNA-binding protein ZC3H12A as a potential mechanism. Knockdown experiments connected this RNA-level regulation to reduced cancer-cell proliferation and migration and weaker tumor-associated macrophage effects, while leaving important questions for validation in more complex models.

• Maraviroc (UK-427857): CCR5 Workflows in Stroke

  2026-09-25

  Use Maraviroc to separate CCR5-dependent HIV-1 entry from downstream inflammatory responses, with practical controls for both antiviral and ischemia-related cell models. A staged workflow helps distinguish receptor-specific effects from solvent, viability, and timing artifacts—while keeping the current limits of stroke evidence clear.

• CCR5-Positive Vesicles in Rheumatoid Arthritis

  2026-09-24

  A 2025 study tests how CCR5-positive extracellular vesicles from rheumatoid arthritis synovial fibroblasts affect chondrocytes and joint damage in experimental arthritis. Removing vesicular CCR5 or delivering Maraviroc in vesicles reduced reported inflammatory and tissue-destructive effects, identifying a potential CCR5-dependent pathway while leaving important questions about mechanism and translation open.

• ABT-199 (GDC-0199): Practical Assay Workflow

  2026-09-24

  ABT-199 (Venetoclax) is a selective BCL-2 probe for testing BCL-2 dependence and apoptosis in hematologic malignancy models. Use it in controlled research assays—not as a diagnostic or medical product—and do not assume activity in models that have not been shown to depend on BCL-2.

• Aztreonam: From Mechanism to Translational Strategy

  2026-09-23

  A translational framework for using Aztreonam to study Gram-negative antibacterial activity, resistance, and selected marrow and hepatic effects—without confusing mechanistic experiments with clinical conclusions.

• Rimonabant (SR141716) in CB1 Withdrawal Research

  2026-09-23

  Rimonabant (SR141716) provides a selective CB1 antagonist challenge for dissecting cannabinoid withdrawal, sex-dependent behavior, and locomotor confounds. This practical guide connects the reference withdrawal model with appetite regulation research, obesity research, and inflammation workflows while emphasizing formulation and interpretation controls.

• How IL-7 Drives Glucocorticoid Resistance in T-ALL

  2026-09-22

  Meyer and colleagues show that glucocorticoids can paradoxically promote resistance in a subset of T cell acute lymphoblastic leukemias by increasing IL-7 receptor signaling and BCL-2 expression. The study connects a normal thymocyte survival mechanism to leukemia treatment response and identifies the IL-7R/JAK/STAT5/BCL-2 axis as a potentially reversible source of steroid resistance.

8031 records 1/536 page Next 12345 下5页 Last page